{"context":{"query":">>uniprot>>bindingdb","source_dataset":"uniprot","target_dataset":"bindingdb"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]P04626,1,P04626,185,3]["},"schema":"id|ligand_name|target_name|target_source_organism|ki|ic50|kd|ec50","mappings":[{"input":"P04626","source":"P04626|Receptor tyrosine-protein kinase erbB-2","targets":["106870|US8592455, 70|Serine/threonine-protein kinase pim-1|Homo sapiens||1 nM||","107057|US8592432, 34|ALK tyrosine kinase receptor|Homo sapiens||20 nM||","112499|DACOMITINIB::US8623883, No. 2::WO2022090481, Example dacomitinib|Epidermal growth factor receptor|Homo sapiens||6.9 nM||","112500|US8623883, No. 6|Epidermal growth factor receptor|Homo sapiens||9.87 nM||","112501|US8623883, No. 7|Epidermal growth factor receptor|Homo sapiens||11.35 nM||","112502|US8623883, No. 8|Epidermal growth factor receptor|Homo sapiens||45.34 nM||","112503|US8623883, No. 9|Epidermal growth factor receptor|Homo sapiens||18.08 nM||","112504|US8623883, No. 10|Epidermal growth factor receptor|Homo sapiens||12.13 nM||","12621|2,4-Diamino-5-ketopyrimidine 39::5-[(2,3-difluoro-6-methoxyphenyl)carbonyl]-2-N-(1-methanesulfonylpiperidin-4-yl)pyrimidine-2,4-diamine::R547::[4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","130909|US10683289, Example Staurosporine::US10927120, Compound staurosporine::US8822500, Stauro- sporine::US9920060, Staurosporine|Cyclin-dependent kinase 2/G1/S-specific cyclin-E1|Homo sapiens||3.93 nM||","13216|BMS-354825::CHEMBL1421::DASATINIB::N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide::N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide::US10294227, Code Dasatinib::US20230348453, Compound A8::cid_3062316::med.21724, Compound Dasatinib|Activated CDC42 kinase 1|Homo sapiens||1.000000 nM||","13246|5-N-(2-chloro-6-methylphenyl)-2-N-cyclopropane-1,3-thiazole-2,5-diamido::BMS-354825 2-Carboxamido-4-hydrido-thiazole Analog 7n::CHEMBL131577::N-(2-chloro-6-methylphenyl)-2-[(cyclopropylcarbonyl)amino]-1,3-thiazole-5-carboxamide|Cyclin-dependent kinase 2|Homo sapiens||>25000||","13268|BMS-354825 2-Heteroarylamino-thiazole Analog 12m::CHEMBL364623::N-(2-Chloro-6-methylphenyl)-2-[(2,6-dimethyl-4-pyrimidinyl)-amino]-1,3-thiazole-5-carboxamide::N-(2-chloro-6-methylphenyl)-2-[(2,6-dimethylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide|Cyclin-dependent kinase 2|Homo sapiens||>25000||","13336|4-[4-(4-fluorophenyl)-2-(4-methanesulfinylphenyl)-1H-imidazol-5-yl]pyridine::4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine::4-{4-(4-fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl}pyridine::CHEMBL10::SB-203580::SB203580::cid_176155|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","13530|4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide::CHEMBL941::Gleevec::Imatinib::Imatinib, 21::N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide::STI-571::STI571::US10906896, Cpd imatinib::US11649218, Example Imatinib::US11725005, Compound imatinib::US9255107, Imatinib::cid_5291::imatinib-CD3::med.21724, Compound 6|Breakpoint cluster region protein|Mouse||38 nM||","13531|4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole::4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol::4-[4-(4-fluorophenyl)-5-(4-pyridyl)-4-imidazolin-2-ylidene]cyclohexa-2,5-dien-1-one::4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol::SB-202190::SB202190::biotinylated SB202190|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","13533|1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::1-[5-tert-butyl-2-(4-methylphenyl)-3-pyrazolyl]-3-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea::1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::1-[5-tert-butyl-2-(p-tolyl)pyrazol-3-yl]-3-[4-(2-morpholinoethoxy)-1-naphthyl]urea::3-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea::BIRB 796::BIRB-796::BIRB-796, 3::CHEMBL103667::D3RKN_73::Doramapimod::US11407771, Compound 43::US8933228, BIRB 796::US9187470, 43 (BIRB-796)::US9242960, BIRB 796::US9260410, BIRB796::cid_156422::diaryl urea compound 10|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","13534|CHEMBL572878::N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide::N-[4-[[4-(4-methylpiperazino)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]thio]phenyl]cyclopropanecarboxamide::VX-680::VX680::cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2ylsulphanyl]-phenyl}-amide|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","13535|4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide::4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-[4-(1-methylethoxy)phenyl]piperazine-1-carboxamide::4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-(4-propan-2-yloxyphenyl)-1-piperazinecarboxamide::4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-N-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide::CHEMBL124660::MLN-518::MLN518::N-(4-isopropoxyphenyl)-4-[6-methoxy-7-(3-piperidinopropoxy)quinazolin-4-yl]piperazine-1-carboxamide::cid_3038522|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","13900|CHEMBL196018::ethyl 4-[(3-chloro-4-fluorophenyl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5a|Epidermal growth factor receptor|Homo sapiens||90 nM||","13901|CHEMBL370934::ethyl 4-[(3-bromophenyl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5b|Epidermal growth factor receptor|Homo sapiens||60 nM||","13902|CHEMBL372112::ethyl 5-ethyl-4-(1H-indazol-5-ylamino)pyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5c|Epidermal growth factor receptor|Homo sapiens||50 nM||","13903|ethyl 5-ethyl-4-{[(1R)-1-phenylethyl]amino}pyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5d|Epidermal growth factor receptor|Homo sapiens||200 nM||","13904|CHEMBL196925::ethyl 4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5e|Epidermal growth factor receptor|Homo sapiens||120 nM||","13905|CHEMBL194349::ethyl 5-ethyl-4-[(4-phenoxyphenyl)amino]pyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5f|Epidermal growth factor receptor|Homo sapiens||610 nM||","13906|CHEMBL425738::ethyl 4-[(1-benzyl-1H-indazol-5-yl)amino]pyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5g|Epidermal growth factor receptor|Homo sapiens||120 nM||","13907|CHEMBL196738::ethyl 4-[(1-benzyl-1H-indazol-5-yl)amino]-5-methylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5h|Epidermal growth factor receptor|Homo sapiens||200 nM||","13908|CHEMBL365606::ethyl 4-[(1-benzyl-1H-indazol-5-yl)amino]-5-(propan-2-yl)pyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5i|Epidermal growth factor receptor|Homo sapiens||200 nM||","13909|CHEMBL438805::ethyl 4-[(1-benzyl-1H-indazol-5-yl)amino]-5-propylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5j|Epidermal growth factor receptor|Homo sapiens||950.0 nM||","13910|CHEMBL197568::ethyl 5-benzyl-4-[(1-benzyl-1H-indazol-5-yl)amino]pyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::pyrrolo[2,1-f][1,2,4]triazine analog 5k|Epidermal growth factor receptor|Homo sapiens||>25000||","13911|4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylic acid::CHEMBL196438::pyrrolo[2,1-f][1,2,4]triazine analog 6|Epidermal growth factor receptor|Homo sapiens||20 nM||","13912|4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxamide::CHEMBL194958::pyrrolo[2,1-f][1,2,4]triazine analog 7a|Epidermal growth factor receptor|Homo sapiens||120 nM||","13913|4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethyl-N-methylpyrrolo[1,2-a][1,2,4]triazine-6-carboxamide::CHEMBL197689::pyrrolo[2,1-f][1,2,4]triazine analog 7b|Epidermal growth factor receptor|Homo sapiens||70 nM||","13914|4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethyl-N,N-dimethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxamide::CHEMBL372293::pyrrolo[2,1-f][1,2,4]triazine analog 7c|Epidermal growth factor receptor|Homo sapiens||200 nM||","13915|CHEMBL372523::benzyl N-{4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazin-6-yl}carbamate::pyrrolo[2,1-f][1,2,4]triazine analog 9a|Epidermal growth factor receptor|Homo sapiens||210 nM||","13916|CHEMBL373025::pyrrolo[2,1-f][1,2,4]triazine analog 10::{4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazin-6-yl}methanol|Epidermal growth factor receptor|Homo sapiens||490.0 nM||","13917|1-benzyl-N-{5-ethyl-6-[(ethylamino)methyl]pyrrolo[1,2-a][1,2,4]triazin-4-yl}-1H-indazol-5-amine::CHEMBL369967::pyrrolo[2,1-f][1,2,4]triazine analog 11|Epidermal growth factor receptor|Homo sapiens||7400 nM||","13918|1-benzyl-N-[6-(ethoxymethyl)-5-ethylpyrrolo[1,2-a][1,2,4]triazin-4-yl]-1H-indazol-5-amine::CHEMBL196548::pyrrolo[2,1-f][1,2,4]triazine analog 12|Epidermal growth factor receptor|Homo sapiens||950.0 nM||","13919|2-{4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazin-6-yl}acetamide::CHEMBL194160::pyrrolo[2,1-f][1,2,4]triazine analog 13|Epidermal growth factor receptor|Homo sapiens||1100 nM||","13920|2-{4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazin-6-yl}acetic acid::CHEMBL372692::pyrrolo[2,1-f][1,2,4]triazine analog 14|Epidermal growth factor receptor|Homo sapiens||1600 nM||","13921|4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethyl-N-[3-(1H-imidazol-1-yl)propyl]pyrrolo[1,2-a][1,2,4]triazine-6-carboxamide::CHEMBL193681::pyrrolo[2,1-f][1,2,4]triazine analog 7d|Epidermal growth factor receptor|Homo sapiens||40 nM||","13922|3-(1H-imidazol-1-yl)propyl 4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazine-6-carboxylate::CHEMBL193368::pyrrolo[2,1-f][1,2,4]triazine analog 8a|Epidermal growth factor receptor|Homo sapiens||170 nM||","13923|2-(1H-imidazol-1-yl)ethyl N-{4-[(1-benzyl-1H-indazol-5-yl)amino]-5-ethylpyrrolo[1,2-a][1,2,4]triazin-6-yl}carbamate::CHEMBL412367::pyrrolo[2,1-f][1,2,4]triazine analog 9b|Epidermal growth factor receptor|Homo sapiens||40 nM||","139540|US10189849, staurosporine::US10307427, Staurosporine::US10329300, Staurosporine::US11091485, Compound Staurosporine::US11542261, Compound staurosporine::US11814388, Compound Staurosporine::US20230312583, Compound staurosporine::US20240025908, Example Staurosporine::US20240246972, Compound Staurosporine::US8889696, Staurosporine::US9051313, Staurosporine::US9586965, Control Staurosporine|Rho-associated protein kinase 1|Homo sapiens||0.627 nM||","139991|US8901140, 5::US9358227, 5|Epidermal growth factor receptor|Homo sapiens||13 nM||","140984|US8916574, Compound 1|Epidermal growth factor receptor|Homo sapiens||11 nM||","140986|US8916574, Compound 3|Epidermal growth factor receptor|Homo sapiens||25 nM||","140988|US8916574, Compound 5|Epidermal growth factor receptor|Homo sapiens||14.61 nM||","149404|AVL-301::CHEMBL3545308::CNX-419::CO-1686::Rociletinib::Tube721::US10167264, Compound CO-1686::US10300058, CO-1686::US10434101, Compound I-4::US11096942, Compound I-4::US8975249, I-4::US9783524, CO-1686|ALK tyrosine kinase receptor|Homo sapiens||145 nM||","149410|US10434101, Compound I-10::US11096942, Compound I-10::US8975249, I-10|Epidermal growth factor receptor [T790M,L858R]|Human||5.50 nM||","15138|5-indazolyl pyridine 11g::5-{5-[(2S)-2-amino-3-phenylpropoxy]pyridin-3-yl}-3-methyl-1H-indazole::A-674563::Biochemistry 469551 Compound 11::indazole-pyridine, 7|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","15244|5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one::5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-a]pyridazin-6-one::5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-6-pyrimido[1,6-b]pyridazinone::5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]pyrimido[1,6-b]pyridazin-6-one::5-(2,6-dichlorophenyl)-9-(2,4-difluorophenyl)sulfanyl-1,3,10-triazabicyclo[4.4.0]deca-2,5,7,9-tetraen-4-one::5-[2,6-bis(chloranyl)phenyl]-2-[2,4-bis(fluoranyl)phenyl]sulfanyl-pyrimido[1,6-b]pyridazin-6-one::VX-745::VX745::cid_3038525|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","15359|(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate::17-(Allylamino)geldanamycin::17-AAG::17AAG::CHEMBL109480::GLD-36::Tanespimycin|ATP-dependent molecular chaperone HSP82|Saccharomyces cerevisiae||8700 nM||","15374|9-butyl-8-(3,4,5-trimethoxybenzyl)-9H-purin-6-amine::9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine::CHEMBL113690::PU3::Purine-Based Inhibitor 1|Heat shock protein HSP 90-alpha/90-beta|Homo sapiens||||3200 nM","164638|BDBM166759::US10604504, Example 223::US11623921, Example 223::US9688629, 123::US9802915, Example 123::US9920031, Example 223|Cytoplasmic tyrosine-protein kinase BMX|Homo sapiens||1.5 nM||","16673|4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide::4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid::BAY 43-9006::BAY 439006::BAY439006::CHEMBL1336::Hit compound, 8::Nexavar::Sorafenib::Sorafenib, 4::US10183928, Sorafenib::US10202365, Compound Sorafenib::US10227329, Compound Sorafenib::US10584114, Compound Sorafenib::US10774070, Compound Sorafenib::US10980809, Example Sorafenib::US11279688, Compound Sorafenib::US11505527, Compound Sorafenib::US11912663, Compound Sorafenib::US9029401, Sorafenib::US9469639, Sorafenib::US9902709, Comparative example 1::Xarelto::cid_216239|Epidermal growth factor receptor|Homo sapiens||110 nM||","17015|(3Z)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one::CHEMBL86755::Indolinone based inhibitor, 1::Oxindole I|ALK tyrosine kinase receptor|Homo sapiens||>50000||","17016|(3Z)-4-methyl-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one::CHEMBL85403::Indolinone based inhibitor, 1a|Epidermal growth factor receptor|Homo sapiens||>100000||","170514|US9085540, 54|Epidermal growth factor receptor|Homo sapiens||1.7 nM||","17055|(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione::(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione::K00587a::LY 333531::LY-333531::LY333531::Ruboxistaurin::cid_153999|3-phosphoinositide-dependent protein kinase 1|Homo sapiens||750 nM||","17747|(3Z)-3-{[4-(dimethylamino)phenyl]methylidene}-2,3-dihydro-1H-indol-2-one::CHEMBL328710::SU 4312::SU4312|Alpha-synuclein|Human|84 nM|||","192316|US9187459, 1|Epidermal growth factor receptor|Homo sapiens||0.4 nM||","192317|US9187459, 2|Epidermal growth factor receptor|Homo sapiens||0.13 nM||","192318|US9187459, 3|Epidermal growth factor receptor|Homo sapiens||0.54 nM||","192319|US9187459, 4|Epidermal growth factor receptor|Homo sapiens||0.51 nM||","192320|US9187459, 5|Epidermal growth factor receptor|Homo sapiens||0.37 nM||","194087|US20230364079, Example Tirabrutinib::US9199997, 9::US9879013, 19(2)|Epidermal growth factor receptor|Homo sapiens||>10000||","195857|US9670213, Compound 002 N-(4-(2-(4-methoxyphenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl)acrylamide|Epidermal growth factor receptor [L858R]|Human||546 nM||","195858|US9670213, Compound 003 N-(4-(2-(4-morpholino-phenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl)acrylamide|Epidermal growth factor receptor [L858R]|Human||4082 nM||","195859|US9670213, Compound 004 N-(4-(2-(4-methoxyphenylamino)-6-methyl-7-oxo-8(7H)-pteridin-yl)phenyl)acrylamide|Epidermal growth factor receptor [L858R]|Human||4877 nM||","195860|US9670213, Compound 005 8-(3-aminophenyl)-2-(4-methoxyphenyl)-7(8H)-pteridin-one|Epidermal growth factor receptor [L858R]|Human||87159 nM||","195861|US9670213, Compound 006 N-(3-(2-(4-methoxyphenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||10 nM||","195864|US9670213, Compound 009 4-(dimethylamino)-N-(4-(2-(4-methoxyphenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl)-2-buteneamide|Receptor-type tyrosine-protein kinase FLT3|Homo sapiens||152 nM||","195865|US9670213, Compound 010 4-(dimethylamino)-N-(3-(2-(4-methoxyphenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl)-2-buteneamide|Receptor-type tyrosine-protein kinase FLT3|Homo sapiens||4387 nM||","195866|US9670213, Compound 011 4-(2 (4-methoxyphenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl acrylate|Epidermal growth factor receptor [L858R]|Human||85 nM||","195868|US9670213, Compound 013 4-(dimethylamino)-N-(3-(7-oxo-2-(phenylamino)-8(7H)-pteridin-yl)phenyl)-2-buteneamide|Epidermal growth factor receptor [L858R]|Human||101 nM||","195870|US9670213, Compound 015 N-(3-(7-oxo-2-(phenylamino)-8(7H)-pteridin-yl)phenyl)acrylamide|Epidermal growth factor receptor [L858R]|Human||12 nM||","195871|US9670213, Compound 016 N-(4-(2-(4-chlorophenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||116 nM||","195872|US9670213, Compound 017 N-(3-(2-(4-chlorophenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||85 nM||","195873|US9670213, Compound 018 N-(3-(2-(4-morpholinophenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||5.83 nM||","195874|US9670213, Compound 019 N-(4-(2-(4-(4-methyl-1-piperazinyl)-phenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||6382 nM||","195875|US9670213, Compound 020 N-(3-(2-(4-(4-methyl-1-piperazinyl)-phenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||1.20 nM||","195876|US9670213, Compound 021 N-(3-(7-oxo-2-(4-(1-piperidinyl)phenylamino)-8(7H)-pteridinyl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||12 nM||","195877|US9670213, Compound 022 N-(3-(7-oxo-2-(4-(1-pyrrolidinyl)phenylamino)-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||13 nM||","195878|US9670213, Compound 023 N-(3-(2-(4-(diethylamino)phenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||16 nM||","195879|US9670213, Compound 024 N-(3-(2-(4-(acetylamino)-phenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||13 nM||","195880|US9670213, Compound 025 4-(8-(3-acrylamidephenyl)-7-oxo-7,8-dihydropteridinyl-2-amino)benzamide|Epidermal growth factor receptor [L858R]|Human||9.64 nM||","195881|US9670213, Compound 026 N-(3-(2-(4-methoxyphenylamino)-6-methyl-7-oxo-8(7H)-pteridin-yl)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||5.93 nM||","195883|US9670213, Compound 028 2-(3-aminophenylamino)-8-(4-methoxyphenyl)-7(8H)-pteridin-one|Epidermal growth factor receptor [L858R]|Human||18881 nM||","195884|US9670213, Compound 029 N-(4-(8-(4-methoxyphenyl)-7-oxo-7,8-dihydro-pteridin-2-amino)phenyl) acrylamide|Epidermal growth factor receptor [L858R]|Human||1318 nM||","195885|US9670213, Compound 030 2-(4-aminophenylamino)-8-(4-methoxyphenyl)-7(8H)-pteridin-one|Epidermal growth factor receptor [L858R]|Human||23758 nM||","195886|US9670213, Compound 031 N-(4-(2-(2-methoxy)-4-(4-methoxy-1-piperazinyl)-phenylamino)-7-oxo-8(7H)-pteridinyl)phenyl)acrylamide|Epidermal growth factor receptor [L858R]|Human||376 nM||","195887|US9670213, Compound 032 N-(3-(2-(2-methoxy-4-(4-methyl-1-piperazinyl)-phenylamino)-7-oxo-8(7H)-pteridin-yl)phenyl)acrylamide|Epidermal growth factor receptor [L858R]|Human||2.36 nM||","209866|PF-06651600::US11111242, Example 5::US20230348487, Example PF-06651600::US9617258, Example 5|Non-receptor tyrosine-protein kinase TYK2|Homo sapiens||>10000||","21|CHEMBL24828::N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine::VANDETANIB::ZD-6474::ZD6474::cid_3081361|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","21079|1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methyl-phenyl)urea::1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea::1-[4-(3-azanyl-1H-indazol-4-yl)phenyl]-3-(2-fluoranyl-5-methyl-phenyl)urea::3-[4-(3-amino-1H-indazol-4-yl)phenyl]-1-(2-fluoro-5-methylphenyl)urea::ABT-869::Aminoindazole, 3::CHEMBL223360::cid_11485656|3-phosphoinositide-dependent protein kinase 1|Homo sapiens|||>10000|","228107|(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-((4aR,7aS)-tetrahydro-2H-[1,4]dioxin[2,3-c]pyrrol-6(3H)-yl)but-2-enamide::US9556191, example 1|Epidermal growth factor receptor [T790M]|Human||8.30 nM||","228108|(e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-((4as,7as)-tetrahydro-2h-[1,4]dioxino[2,3-c]pyrrol-6(3h)-yl)but-2-enamide::US9556191, example 2|Epidermal growth factor receptor [T790M]|Human||16.0 nM||","228109|(e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-4-((4ar,7as)-tetrahydro-2h-[1,4]dioxin[2,3-c]pyrrol-6(3h)-yl)but-2-enamide::US9556191, example 3|Epidermal growth factor receptor [T790M]|Human||6.20 nM||","228110|(e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((s)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-((4ar,7as)-tetrahydro-2h-[1,4]dioxino[2,3-c]pyrrol-6(3h)-yl)but-2-enamide::US9556191, example 5|Epidermal growth factor receptor [T790M]|Human||6.80 nM||"]}]}